Multiple System Atrophy (MSA) is a progressive, rare neurodegenerative disorder adversely affecting the autonomic nervous system, movement, balance, coordination, and various bodily functions.

Multiple system atrophy — that is the preferred name — is a degenerative neurological disorder. It’s complex and characterized by a constellation of neurologic symptoms related to your autonomic ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

- Data Presented at the International Congress of Parkinson’s Disease and Movement Disorders - The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a ...

ATH434 improves daily function and reduces brain iron in patients with multiple system atrophy, a rare, fatal neurodegenerative disorder with no approved treatments.

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Several age-related neurodegenerative disorders are characterized by the deposition of aberrantly folded proteins. The histopathological hallmark of synucleinopathies is the deposition of ɑ-synuclein ...

For as long as Steve Gorman can remember, baseball has provided a connection to his older brother Jim. When Steve moved from Baltimore to Kentucky in 1975, he kept up with his beloved Orioles through ...

Levels of Aβ42 in the cerebrospinal fluid were about 50 percent higher in people with multiple system atrophy than people with Alzheimer's disease (effect size = 1.55, p <0.0001). For comparison, the ...

In an exclusive interview, Alterity Therapeutics’ ( ATHE) CEO David Stamler met with The Fly to discuss the company, the biotech industry, ongoing trials, upcoming milestones and much more. Published ...

DelveInsight's“ Multiple System Atrophy Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It ...

Meta-analysis showed that the levels of neurogranin in the cerebrospinal fluid of people with multiple system atrophy were only about 40 percent those of people with Alzheimer's disease (effect size = ...